Scholars Central

Conference abstractPublished 24 Jun 2014

Thyroid hormones growth factor effect in ovarian cancer: Old players, new game

Authors: Elena Shinderman

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Ovarian carcinoma is the fifth most common cancer in women. As this disease remains challenging and highly resistant, novel treatments are urgently needed. α v β 3 integrin is a plasma membrane receptor which is over-expressed on many cancer cells, including ovarian cancer. This receptor recognizes RGD motifs on extra cellular proteins and takes part in adhesion and signaling processes. Recently, a novel non-RGD site has been described, binding mainly thyroid hormones (T3 and T4) and activating the MAPK pathway. It was aimed to study the mitogenic effects of the thyroid- α v β 3 axis, for the first time in ovarian cancer models. Methods: Ovarian cancer cell lines (OVCAR-3, SKOV-3 and A2780) were grown with/without T3/T4 (0.1nM-1 μ M) in the presence/absence of integrin antagonists and analyzed by: cell counts (FACS, CyQuant), viability (WST-1), proliferation (BrdU), cell cycle (FACS,PI), cell death (Annexin-PI, FACS), α v β 3 expression (FACS, IF) and MAPK signaling (Westerns/IF). Results: It is shown that supra-physiological T3 (1nM) and physiological T4 (100nM) concentrations increase cell viability and proliferation in ovarian cancer cells. This increase was accompanied by a reduction in cell death. Following T3/T4 treatments, a quick and long lasting MAPK pathway activation was observed. These effects were efficiently reversed by several integrin blockers, in a dose dependent manner, indicating involvement of this integrin in the growth promoting action of thyroid hormones. Conclusions: Thyroid hormones exhibit growth-factor qualities in ovarian cancer cells which appear to be α v β 3 mediated. Therefore, the study proposes that blocking this axis is a novel treatment paradigm which is yet to be explored

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “Elena Shinderman”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels